Home
Per Eystein Lønning's picture

Per Eystein Lønning

Professor
  • E-mailPer.Lonning@uib.no
  • Phone+47 55 97 20 10+47 55 97 20 27
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen

Professor Per Eystein Lønning is the head of the breast cancer research group at Mohn cancer research laboratory. he has a continuous work record in cancer therapy and science since 1982. He was employed as a consultant in oncology at Haukeland University Hospital in 1990, and became professor at the University of Bergen in 1992. The breast cancer group currently includes about 20 members. The work is centered on translational research in breast cancer; the group however also runs projects related to colorectal cancers and melanomas. The team include senior researchers 7 postdocs / PhD candidates as well as technical staff members in the laboratory but also physicians seeing patients at the Department of Oncology, several of whom in addition work part-time on their projects in the laboratory. Professor Lønnings main area of interest has been mechanism related to therapy failure in the area of endocrine as well as chemotherapy for breast cancer. In addition, he has had an interest in genetic and epigenetic cancer risk factors. His current main field of research relates to chemotherapy resistance.

Academic article
  • 2010. Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research. 1790-1801.
  • 2010. Impact of aromatase inhibitors on bone health in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 294-299.
  • 2010. Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. Clinical Cancer Research. 3356-3367.
  • 2010. Evolution of endocrine adjuvant therapy for early breast cancer. Expert Opinion on Investigational Drugs. S19-S30.
  • 2010. Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding? Journal of Steroid Biochemistry and Molecular Biology. 288-293.
  • 2010. Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. BBA - Molecular Cell Research. 386-395.
  • 2010. Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status. Journal of Steroid Biochemistry and Molecular Biology. 237-241.
  • 2009. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. Journal of Steroid Biochemistry and Molecular Biology. 31-41.
  • 2009. Tailored targeted therapy for all: a realistic and worthwhile objective? Breast Cancer Research.
  • 2009. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer. 1253-1260.
  • 2009. Molecular classes of breast cancer and their clinical relevance. Current Breast Cancer Reports. 183-189.
  • 2009. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research. 5331-5339.
  • 2009. A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clinical Cancer Research. 4165-4173.
  • 2008. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • 2008. Pathway based analysis of SNPs with relevance to 5-FU therapy: Relation to intratumoral mRNA expression and survival. International Journal of Cancer. 577-585.
  • 2008. Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. Clinical Cancer Research. 6330-6335.
  • 2008. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Research. 5562-5571.
  • 2008. Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference? Anti-Cancer Drugs. S11-S13.
  • 2008. Experience with exemestane in the treatment of early and advanced breast cancer. Expert Opinion on Drug Metabolism & Toxicology. 987-997.
  • 2008. Endocrine treatment - "old-fashioned" therapy becoming redundant in an era of molecular medicine? Breast Care. 388-390.
  • 2008. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLOS ONE. 15 pages.
  • 2008. Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. Journal of Steroid Biochemistry and Molecular Biology. 196-202.
  • 2008. Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? The Oncologist. 829-837.
  • 2008. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. Journal of Steroid Biochemistry and Molecular Biology. 90-95.
  • 2007. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncologica.
  • 2007. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. Journal of Steroid Biochemistry and Molecular Biology. 27-34.
  • 2007. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet. 559-570.
  • 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research. 7267-7278.
  • 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research. 7267-7278.
  • 2007. Mutations and polymorphisms of the p21B transcript in breast cancer. International Journal of Cancer. 908-910.
  • 2007. Breast cancer prognostication and prediction: are we making progress? Annals of Oncology. viii3-viii7.
  • 2007. Aromatase inhibitors-Socioeconomical issues. Journal of Steroid Biochemistry and Molecular Biology. 55-61.
  • 2007. Adjuvant endocrine treatment of early breast cancer. Hematology/Oncology Clinics of North America. 223-238.
  • 2007. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenetics & Genomics. 127-136.
  • 2006. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clinical and Experimental Immunology. 53-58.
  • 2006. The novel p21 polymorphism p21(G251A) is associated with locally advanced breast cancer. Clinical Cancer Research. 6000-6004.
  • 2006. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunology and Immunotherapy. 1280-1284.
  • 2006. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. Journal of Cell Science. 3284-3295.
  • 2006. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 2914-2918.
  • 2006. Expression of full-length p35 and its isoform DELTAp53 in breast carcinomas in relation to mutation status and clinical parameters. Molecular Cancer. 47.
  • 2006. Evaluation of MetriGenix custom 4D (TM) arrays applied for detection of breast cancer subtypes. BMC Cancer. 6 pages.
  • 2006. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Annals of Oncology. 217-225.
  • 2006. Commentary on: Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer? Nature Clinical Practice Oncology. 356-357.
  • 2006. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 2968-75.
  • 2006. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. Journal of Gene Medicine. 1131-1140.
  • 2006. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes, Chromosomes and Cancer. 1155-1163.
  • 2005. Genomics-based prognosis and therapeutic prediction in breast cancer. The Journal of the National Comprehensive Cancer Network. 291-300.
  • 2005. Genomics in breast cancer - therapeutic implications? Nature Clinical Practice Oncology. 26-33.
  • 2005. Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 105-111.
  • 2005. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncologica. 23-31.
  • 2005. Aromatase inhibitors - socio-economical issues. Journal of Steroid Biochemistry and Molecular Biology. 137-142.
  • 2004. PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Experimental Cell Research. 58-73.
  • 2004. Mutation of GATA3 in human breast tumors. Oncogene. 7669-7678.
  • 2004. Alternative splicing and mutation status of CHEK2 in stag III breast cancer. Oncogene. 8535-8544.
  • 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 8418-8423.
  • 2003. Predictive value of tumour cell proliferation in locally advanced breast cancer treated neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • 2002. The role of aromatase inactivators in the treatment of breast cancer. International Journal of Clinical Oncology. 265-270.
  • 2002. The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids. Journal of Steroid Biochemistry and Molecular Biology. 95-102.
  • 2002. Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer. Breast Cancer Research and Treatment. 161-175.
  • 2001. The insulin-like growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression, and antiretroviral therapy. Journal of Clinical Endocrinology and Metabolism. 227-233.
  • 2001. Resistance to Endocrine Therapy of Breast Cancer: Recent Advances and Tomorrow`s Challenges. Clinical Breast Cancer. 297-308.
  • 2001. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 7952-7957.
  • 2001. Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer. British Journal of Cancer. 74-77.
  • 2001. Pharmacokinetics and metabolism of formestane in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 39-47.
  • 2001. Microarrays in primary breast cancer ¿ lessons from chemotherapy studies. Endocrine-related cancer. Endocrine-Related Cancer. 259-263.
  • 2001. Microarrays in primary breast cancer -lessons from chemotherapy studies. Endocrine-Related Cancer. 259-263.
  • 2001. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clinical Cancer Research. 1230-1236.
  • 2001. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Research and Treatment. 111-116.
  • 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 10869-10874.
  • 2001. Exemestane: a review of its clinical efficacy and safety. Breast. 198-208.
  • 2001. Alterations in the insulin-like growth factor-system during treatment with diethylstilbestrol in patients with metastatic breast cancer. British Journal of Cancer. 147-151.
  • 2000. Screening breast cancer patients for ATM mutations found in Norwegian AT patients. British Journal of Cancer. 1650-1653.
  • 2000. Screening breast cancer patients for ATM mutations found in Norwegian AT patients. British Journal of Cancer. 1650-1653.
  • 2000. Pharmacology and clinical experience with exemestane. Expert Opinion on Investigational Drugs. 1897-1905.
  • 2000. Is there a growing role for endocrine therapy in the treatment of breast cancer? Drugs. 11-21.
  • 2000. Is there a growing role for endocrine therapy in the treatment of breast cancer? Drugs. 11-21.
  • 2000. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 1329-1333.
  • 2000. Exemestane in breast cancer: Current status and future directions. Clinical Breast Cancer. S28-S33.
  • 2000. Endocrine therapy for treatment of breast cancer. Polish Oncology. 50-53.
  • 2000. Clinico-pharmacological aspects of different hormone treatments. European Journal of Cancer. S81-S82.
  • 2000. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology. 2234-2244.
  • 2000. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 259-264.
  • 2000. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 259-264.
  • 1999. TP53 as a predictor of response to chemotherpy in breast cancer. RSO Scientific Updates. 73-88.
  • 1999. TP53 as a predictor of response to chemotherapy in breast cancer. Review. European School of Oncology Scientific Updates. 73-88.
  • 1999. TP53 as a predictor of response to chemotherapy in breast cancer. European School of Oncology Scientific Updates. 73-88.
  • 1999. Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters. 73-77.
  • 1999. Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters. 73-77.
  • 1999. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer. 891-898.
  • 1999. Plasma estrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking. Endocrinology. 265-270.
  • 1999. Influence of TP53 gene alterations and Her-2 expression on the respons to treatment with doxorubicin in locally advanced breast cancer. (Abs. no. 227). Breast Cancer Research and Treatment.
  • 1999. Effect of treatment with megestrol acetate on the IGF-system: Time and dose dependency. European Journal of Cancer. 1070-1075.
  • 1999. Cross-resistance to different aromatase inhibitors in breast cancer treatment. Endocrine-Related Cancer. 251-257.
  • 1999. CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to SP-1. Cancer Research. 2825-2828.
  • 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • 1998. Pharmacological profiles of exemestane and formestane steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Research and Treatment. 45-52.
  • 1998. Pharmacological and clinical profile of anastrozole. Breast Cancer Research and Treatment. s53-s57.
  • 1998. Microencapsulated octreotide pamoate in advanced cancer. British Journal of Cancer. 14-20.
  • 1998. Kinetics of total plasma homocysteine during basal conditions. Clinical Chemistry. 1886-1891.
  • 1998. Kinetics of plasma total homocysteine in patients receiving high-dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • 1998. Kinetics of plasma total homocysteine in patients receiving high- dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • 1998. Influence of treatment with onapristone on the IGF-system in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 159-163.
  • 1998. Influence of treatment with aminoglutethimide on plasma and red-blood-cell gluthatione status in breast cancer patients. Cancer Chemotherapy and Pharmacology. 46-52.
  • 1998. Influence of droloxifene on metastatic breast cancer as first line endocrine treatment. Acta Oncologica. 365-368.
  • 1998. Influence of dexaminoglutethimide, optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patie. Journal of Clinical Endocrinology and Metabolism. 2687-2693.
  • 1998. Influence of Droloxifene on Metastatic Breast Cancer as First Line Endocrine Treatment. Acta Oncologica. 365-368.
  • 1998. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breat cancer patients. Clinical Cancer Research. 2089-2093.
  • 1998. Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clinical Cancer Research. 2125-2128.
  • 1998. Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clinical Cancer Research. 2125-2128.
  • 1998. Aromatase inhibitors and their future role in postmenopausal women with early breast cancer. British Journal of Cancer. 12-15.
  • 1998. Alterations in the insulin-like growth factor system during the menstrual cycle in normal women. Maturitas. 259-265.
  • 1997. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. Journal of Steroid Biochemistry and Molecular Biology. 255-260.
  • 1997. Exemestane experience in breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology. 151-155.
  • 1997. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clinical Cancer Research. 1101-1108.
  • 1997. Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • 1997. Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • 1997. Differential influence of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • 1997. Different effects of carbamazepine and valproate monotheraphy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • 1997. Anastrozole - A new generation in aromatase inhibition: Clinical pharmacology. Oncology. 11-14.
  • 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1997. Absence of p21 Expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1996. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. European Journal of Cancer. 789-792.
  • 1996. Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • 1996. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • 1996. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clinical Cancer Research. 1515-1521.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Pharmacology of new aromatase inhibitors. Breast. 202-208.
  • 1996. Insulin-like growth factors in breast cancer. Acta Oncologica. 19-22.
  • 1996. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. International Journal of Cancer, Predictive Oncology. 335-339.
  • 1996. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Research and Treatment. 335-341.
  • 1996. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-I IGFBP-3 in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 167-171.
  • 1996. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • 1996. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisatin and plasma oestrogen levels in post-menopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • 1996. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF)I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. Journal of Clinical Endocrinology and Metabolism. 2216-2221.
  • 1996. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: A cross-over study. Clinical Endocrinology. 727-732.
  • 1996. Aromatase inhibition for breast cancer treatment. Acta Oncologica. 38-43.
  • 1995. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • 1995. Relations between sex hormones, sex hormone binding globulin insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • 1995. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • 1995. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • 1995. Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Research and Treatment. 287-297.
  • 1995. Insulin-like growth factors in breast and prostatic cancer. Endocrine-Related Cancer. 153-169.
  • 1995. Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • 1995. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • 1995. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 193-195.
  • 1995. Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • 1995. Determination of droloxifene and two metabolites in serum by high pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • 1995. Alterations in plasma IGF-I caused by hormone manipulation; of relevance to the mechanism of action and acquired resistance to endocrine treatment in breast cancer? Endocrine-Related Cancer. 127-130.
  • 1992. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • 1992. Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
  • 1992. Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
  • 1992. Disposition of new endocrine drugs used in the treatment of advanced breast cancer. Clinical Pharmacokinetics. 327-358.
  • 1992. Disposition of new endocrine drugs used in the treatment of advanced breast cancer. Clinical Pharmacokinetics. 327-358.
  • 1990. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-2. A differential effect of megestrol acetate a medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin. Journal of Steroid Biochemistry. 105-109.
  • 1990. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-1. General findings. Journal of Steroid Biochemistry. 99-104.
Academic lecture
  • 2012. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
  • 2011. GDPD5 expression correlates with choline metabolite profiles in human breast cancer.
  • 2010. Predicting long-term survival for breast cancer patients by HR MAS metabolic profiling during neoadjuvant chemotherapy.
  • 2010. Predicting long-term breast cancer survival in patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
  • 1999. Neoadjuvant Treatment with Anastrozole ('ARIMIDEX') Causes Profound Suppression of Intra-Tumor Estrogen Levels.
  • 1999. Comparison of the effects of neoadjuvant 'Arimidex'(Anastrozole) on plasma and intra-tumor tissue estrogen levels in postmenopausalbreast cancer patients.
  • 1995. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer.
  • 1994. Treatment of postmenopausal breast cancer patients with the steroidal aromatase inhibitor Exemestane (FCE 24304).
  • 1994. Influence of megestrol acetate, aminoglutethimide and 4-hydroxyandrostendione on plasma IGF-I in breast cancer patients.
Academic anthology/Conference proceedings
  • 2004. Expression profiling of breast cancer: From molecular portraits to clinical utility. John Wiley & Sons.
Abstract
  • 2010. Exploring chemoresistance in vivo; are we making progress. European Journal of Cancer. 155-155.
  • 2009. Proteomics analysis of tissue samples obtained before and during letrozole treatment in postmenopausal patients with locally advanced breast cancer. Cancer Research. 214S-214S.
  • 2009. DETERMINANTS OF INTRATUMOURAL OESTRADIOL (E2) CONCENTRATIONS IN POSTMENOPAUSAL BREAST CANCER: ROLES FOR OESTROGEN RECEPTOR (ER) AND 17B-HYDROXYSTEROID DEHYDROGENASE 7 (HSD17B7). Annals of Oncology. 51-52.
  • 2008. ER/PGR and prediction of response to hormonotherapy. Can we do better? Annals of Oncology. 29-29.
  • 2008. Are there any difference between third-generation aromatase inhibitors? European Journal of Cancer. 52-52.
  • 2008. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • 2007. Promotor hypermethylation of MGMT, RAR-beta2, RASSF1A and p16 in metastatic malignant melanoma. Proceedings of the American Association of Cancer Research. 684.
  • 2007. Biological lessons from adjuvant therapy. European Journal of Cancer. 25-25.
  • 2007. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • 2005. The SNP309HDM2 polymorphism is associated with chemoresistance and poor survival in breast cancers harboring mutations in the TP53 gene. Breast Cancer Research and Treatment. S160-S160.
Academic literature review
  • 2016. Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. 1580-1583.
  • 2015. Estradiol measurement in translational studies of breast cancer. 26-31.
  • 2014. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. 681-700.
  • 2013. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. 5315-5330.
  • 2013. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. R183-R201.
  • 2012. P53 and its molecular basis to chemoresistance in breast cancer. S23-S30.
  • 2011. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. 503-514.
  • 2011. Exploring breast cancer estrogen disposition: The basis for endocrine manipulation. 4948-4958.
  • 2010. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. 1825-1836.
  • 2010. Molecular basis for therapy resistance. 284-300.
  • 2009. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? 527-535.
  • 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 6-22.
  • 2009. Additive endocrine therapy for advanced breast cancer - back to the future. 1092-1101.
  • 2008. Indications and limitations of third-gene ration aromatase inhibitors. 723-739.
  • 2007. Breast cancer prognostication and prediction in the postgenomic era. 1293-1306.
  • 2006. Aromatase inhibitors as adjuvant treatment of breast cancer. 53-61.
  • 2004. Aromatase inhibitors in breast cancer. 179-189.

More information in national current research information system (CRIStin)

Fields of competence